GigaGen CEO David Johnson to Present on Development of Recombinant Polyclonal Therapies for Infectious Disease at 10th Annual PEGS Summit Europe
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 /PRNewswire/ -- GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the development of highly diverse, functional antibodies for infectious disease utilizing Surge technology at the 10th Annual Protein & Antibody Engineering Summit (PEGS) in Europe. Dr. Johnson's invited podium presentation is titled "Microfluidics and Genomics for Polyclonal and Monoclonal Antibody Drugs for Infectious Disease" and will take place during the Engineering Antibodies conference at 11:15 a.m. GMT on November 13, 2018, at the Libson Congress Center in Libson, Portugal.
"Surge allows us an unprecedented understanding of the immune system to develop first-in-class recombinant polyclonal antibody therapies against a wide range of diseases," said Dr. Johnson. "During PEGS, I look forward to presenting pre-clinical validation data for recombinant polyclonal hyperimmune therapies for pneumococcus and Haemophilus influenzae B. In the past, recombinant polyclonal drugs have been too complex to bioengineer, forcing manufacturers to rely on generating the drugs from human and animal plasma. Using Surge's power to copy natural immune repertoires, we can now bioengineer recombinant polyclonal therapies, which are more potent and consistent than plasma drugs, for patients with infectious disease and primary immune deficiency."
A preview of Dr. Johnson's talk can be accessed at http://www.pegsummiteurope.com/phage-display/#3
About GigaGen
GigaGen is a privately-held, preclinical biopharmaceutical company developing novel antibody therapies to treat diseases of immune dysregulation. GigaGen's deep understanding of immune dysregulation is enabled by industry-leading technology that quickly captures the genetic makeup of entire immune repertoires to analyze B cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. GigaGen has a robust internal pipeline consisting of novel antibodies against immuno-oncology targets, in addition to the first recombinant intravenous immunoglobulin (IVIG) for patients with immune deficiency. For more information visit www.GigaGen.com.
SOURCE GigaGen Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article